Invested In Biomedical Innovation

In June 2017, Lilly announced completion of a $90 million expansion of its Biotechnology Center in San Diego, California. This space will help foster and accelerate the discovery of medicines within the company’s core therapeutic areas of immunology, diabetes, oncology and neurodegeneration, as well as the emerging area of pain.

The expansion is a part of Lilly’s recent commitment to invest $850 million in U.S. operations, based on the potential for growth and the company’s long-standing investment in the U.S. market. Nearly $250 million of Lilly’s $850 million capital investments will be dedicated to supporting its research and development centers around the U.S. In 2017, Lilly plans to spend approximately $5 billion on global R&D, nearly $4 billion of which will be invested in U.S.-based programs.

San Diego has been an important research hub for Lilly following its acquisitions of Applied Molecular Evolution, Inc., in 2004 and Structural Genomics in 2008. The Biotechnology Center was officially established in 2009 and is located near the University of California, San Diego, among other prominent biomedical research institutes.

Biotechnology Center At a Glance

  • The Biotechnology Center is located at 10290 Campus Point Drive, San Diego, CA 92121.
  • The center features a new technologically-advanced laboratory – the Lilly Life Science Studio – and an additional 180,000 square feet of working space, which is an increase of 145 percent compared to the former facility. The Lilly Life Science Studio will allow researchers across the globe to remotely design, synthesize and screen investigational molecules in an unprecedented manner.
  • More than 200 people are currently working at the center in the disciplines of biotechnology, chemistry, immunology and immunological clinical development. Click here to learn more about career opportunities.

Click here for a media toolkit.

Not media? No worries, you can explore more below.

Explore Lilly's Biotech Center
Discovery
Dave Ricks Chairman and CEO, Lilly

"At Lilly, we’re glad to be part of the fountain of economic activity in California. We’ve invested steadily here in San Diego for more than a decade, including today’s $90 million announcement. It’s part of $850 million of capital investments Lilly is making across the U.S. this year."

In the Lab in San Diego
Discovery
Jan Lundberg, Ph.D. Executive Vice President, Science and Technology, and President, Lilly Research Laboratories

"For 141 years, Lilly has pursued an innovation-based strategy to discover, develop and deliver cutting-edge medicines. That commitment continues today as we focus our efforts at the intersection of breaking science and unmet medical needs in San Diego."

Tom Bumol Senior Vice President, Biotechnology and Immunology Research, Lilly

"By merging our biotechnology and next generation discovery chemistry capabilities in San Diego, we believe we’ve created a world-class collaboration site for biopharmaceutical R&D. We’ve proven we can deliver innovation across the finish line and we want to do even more in the future."

Spirit of Discovery
Discovery
Mr. Eli Lilly Grandson of Colonel Eli Lilly, Company Founder

"Research is the heart of the business, the soul of the enterprise."

Learn About Clinical Research
Discovery
Three Lilly Scientists Share What Motivates Them
Discovery
An R&D Leader, From Ski Slopes to Science Lab
Discovery
Science Storyteller Shares Her Own
Discovery
Beating Diabetes
video
Beating Back Polio
video
Alzheimer’s Researcher, Determined to Discover
Discovery
Inspired By Patients … and Fireflies
Discovery
Scientist Sets Down Deep Roots
Discovery
Lilly Collaborates with NIH
Discovery
6 Dave Ricks Thoughts From JPM
Partners
Growing and Ready to Collaborate
Discovery
Open Innovation Drug Discovery
Discovery
Accelerating the Flow of Medicines
video